Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

FDA Review of Gleevec Promotional Material

In April 2010, the U.S. Food and Drug Administration issued a warning letter to Novartis Pharmaceuticals Corp. about two websites sponsored by Novartis promoting its cancer treatment drug Gleevec. The FDA found these websites “false and misleading because they promote the drug for an unapproved use, fail to disclose the risks associated with the use of Gleevec and make unsubstantiated dosing claims. Therefore, these websites misbrand the drug in violation of the Federal Food, Drug, and Cosmetic Act…and FDA implementing regulations.” It also found that these promotional materials were not submitted to FDA prior to publication in accordance with the law.

Misconduct Type
Health
Enforcement Agency
Health and Human Services
Contracting Party
None
Court Type
N/A
Disposition
Investigative Finding
Date of FDA Warning Letter
4/21/2010
Contractors Involved Penalty
Total
Novartis AG $0
Further Information Released
FDA Warning Letter 8/10/2010

Federal Contractor Misconduct Database